| 347.86 14.98 (4.5%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 411.87 |
1-year : | 481.06 |
| Resists | First : | 352.63 |
Second : | 411.87 |
| Pivot price | 319.19 |
|||
| Supports | First : | 308.85 |
Second : | 281.79 |
| MAs | MA(5) : | 333.49 |
MA(20) : | 313.64 |
| MA(100) : | 288.16 |
MA(250) : | 294.59 |
|
| MACD | MACD : | 11.6 |
Signal : | 8.7 |
| %K %D | K(14,3) : | 91.9 |
D(3) : | 87 |
| RSI | RSI(14): 75.5 |
|||
| 52-week | High : | 352.63 | Low : | 236.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIO ] has closed above the upper band by 1.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 32.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 352.94 - 355.42 | 355.42 - 357.36 |
| Low: | 325.15 - 327.67 | 327.67 - 329.63 |
| Close: | 344.44 - 348.49 | 348.49 - 351.64 |
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Wed, 05 Aug 2026
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Wed, 05 Aug 2026
Bio-Rad Laboratories Q2 2026 Earnings Call Transcript - MarketBeat
Wed, 05 Aug 2026
Bio-Rad Laboratories Q2 Earnings Call Highlights - Yahoo Finance
Tue, 04 Aug 2026
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates - Yahoo Finance
Tue, 04 Aug 2026
Earnings call transcript: Bio-Rad tops Q2 2026 estimates, shares fall after hours - Investing.com
Tue, 04 Aug 2026
Bio-Rad Laboratories (BIO) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 94.4 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 6.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 255.36 |
| Profit Margin | 6.5 % |
| Operating Margin | 5.7 % |
| Return on Assets (ttm) | 1.7 % |
| Return on Equity (ttm) | 2.4 % |
| Qtrly Rev. Growth | 1.1 % |
| Gross Profit (p.s.) | 62.21 |
| Sales Per Share | 119.35 |
| EBITDA (p.s.) | 20.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 510 (M) |
| Levered Free Cash Flow | 230 (M) |
| PE Ratio | 57.88 |
| PEG Ratio | 4 |
| Price to Book value | 1.36 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 14.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|